Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $33.50 Average PT from Analysts
Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have received a consensus recommendation of “Buy” from the six research firms that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issued ratings on the stock in […]
More Stories
Short Interest in Navient Co. SR NT 6% 121543 (NASDAQ:JSM) Expands By 311.7%
Navient Co. SR NT 6% 121543 (NASDAQ:JSM – Get Free Report) was the recipient of a large increase in short...
First Trust Exchange-Traded Fund IV First Trust Tactical High Yield ETF (NASDAQ:HYLS) Sees Significant Drop in Short Interest
First Trust Exchange-Traded Fund IV First Trust Tactical High Yield ETF (NASDAQ:HYLS – Get Free Report) saw a large decrease...
iShares 5-10 Year Investment Grade Corporate Bond ETF (NASDAQ:IGIB) Sees Significant Decline in Short Interest
iShares 5-10 Year Investment Grade Corporate Bond ETF (NASDAQ:IGIB – Get Free Report) was the recipient of a significant decline...
EuroDry Ltd. (NASDAQ:EDRY) Sees Large Growth in Short Interest
EuroDry Ltd. (NASDAQ:EDRY – Get Free Report) was the target of a significant growth in short interest in December. As...
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Sees Significant Growth in Short Interest
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Free Report) was the target of a significant growth in short interest in the...
Senmiao Technology (NASDAQ:AIHS) versus HyreCar (NASDAQ:HYRE) Critical Comparison
Profitability This table compares Senmiao Technology and HyreCar’s net margins, return on equity and return on assets. Net Margins Return...